ESG Report 2024

26 As at the year end, the Group had a total of 43 projects in the pipeline for the development of generic drugs and new drugs. Among these projects, 11 have entered the clinical stage, 6 are awaiting clinical trial approval for production, and 24 are in the pre-clinical research stage. Furthermore, the Group actively responds to the national requirements for consistency evaluation of generic drugs, with a total of 24 projects having obtained approval for consistency evaluation and an additional 8 projects in progress. The Group currently has several key research and development products, as shown in the chart above (R&D Pipeline), and it is expected that these products will lay a solid foundation for the Group's sustainable development in the future. In addition, building upon the foundation of excellent product quality, production processes, and equipment, the Group actively seeks breakthroughs and strives for efficiency. We have successfully achieved numerous scientific research outcomes, not only providing the public with more high-quality pharmaceutical products but also enhancing the operational and production efficiency of the Group. UBT251 is a long-acting GLP-1/GIP/GCG triple- target receptor agonist with potent activity against glucagon-like peptide-1 (GLP-1), glucose- dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors. It regulates appetite and energy metabolism, reduces blood glucose and body weight, and improves hepatic steatosis. During the Year, the Phase Ia clinical trial in healthy Chinese subjects has been completed. Results demonstrate that UBT251 exhibits significant weight loss effects, along with favorable safety and tolerability in healthy subjects, suggesting potential for even greater metabolic benefits and weight reduction in obese populations. Currently, the Group is the first enterpise in China and the second in the world to develop such long-acting GLP-1/GIP/GCG triple agonist using chemically synthesised peptide methods. UBT251 Injection Completes Phase Ia Clinical Trial Endocrinology/ Metabolism Field Insulin Degludec is a new generation of long- acting basic insulin analogues, with an action time of 42 hours and features of stable glucose control and high safety. Currently, Insulin Degludec is classified as a Class B drug in the National Medical Insurance Catalogue (2023 edition). Insulin Degludec's Marketing Application Accepted by National Medical Products Administration TUL 1 2 1 0 1 i s a n ew g e n e r a t i o n sma l l - molecule RASP (Reactive Aldehyde Species) inhibitor. Its mechanism of action involves trapping harmful aldehydes released during inflammatory responses, thereby alleviating inflammation and breaking the vicious cycle of chronic inflammation. It is being developed for the treatment of ophthalmic such as dry eye syndrome. In May of this year, TUL12101 eye drops successfully completed a Phase I clinical trial in healthy Chinese subjects, demonstrating good safety and tolerability. In October, the first subject was enrolled in the Phase IIa clinical study of TUL12101 in China. Currently, the Group is the first in China and the second in the world to develop a RASP inhibitor for therapeutic use. TUL12101 Eye Drops Completes First Subject Enrollment in Phase IIa Clinical Trial Mupirocin Ointment is a Class A OTC topical dermatological medication indicated for the treatment of primary skin infections caused by Gram-positive cocci, as well as secondary skin infections such as eczema with superinfection and superficial trauma with infection. As a broad- spectrum antibiotic, Mupirocin Ointment demonstrates excellent efficacy against common pathogenic strains and is included in both the National Essential Drug List (2018 edition) and the National Basic Medical Insurance Drug List (2023 edition) as a Class B drug’s category. Its characteristics include potent antibacterial activity, minimal local absorption, low tendency to develop cross-resistance, making it a stable- quality, highly effective household topical medication. Mupirocin Ointment (Specification: 2% (5g:0.1g)) Approved for Marketing Topical Dermatology Field Ophthalmology Field Endocrinology/ Metabolism Field Environmental, Social and Governance Report 2024 The United Laboratories International Holdings Limited